EWS-FLI-1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology

Cancer

Volumn 120, Issue 4, 2014, Pages 579-588

  Zhou, Zhichao ^a   Yu, Ling ^a   Kleinerman, Eugenie S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Ewing sarcoma; EWS FLI 1; RE1 silencing transcription factor (REST); tumor growth; tumor vasculature

Indexed keywords

EWING SARCOMA; EWS-FLI-1; RE1-SILENCING TRANSCRIPTION FACTOR (REST); TUMOR GROWTH; TUMOR VASCULATURE;

ANIMALS; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL DIFFERENTIATION; CELL HYPOXIA; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NEURONS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEIN C-FLI-1; REPRESSOR PROTEINS; RNA-BINDING PROTEIN EWS; SARCOMA, EWING; STEM CELLS;

EID: 84893725623     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28555     Document Type: Article

References (24)

1. Riggi N, Stamenkovic I,. The biology of Ewing sarcoma. Cancer Lett. 2007; 254: 1-10. (Pubitemid 47058800)
2. Barker LM, Pendergrass TW, Sanders JE, Hawkins DS,. Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol. 2005; 23: 4354-4362. (Pubitemid 46207009)
3. Miser JS, Krailo MD, Tarbell NJ, et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide-a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol. 2004; 22: 2873-2876. (Pubitemid 41079906)
4. Rorie CJ, Thomas VD, Chen P, Pierce HH, O'Bryan JP, Weissman BE,. The Ews/Fli-1 fusion gene switches the differentiation program of neuroblastomas to Ewing sarcoma/peripheral primitive neuroectodermal tumors. Cancer Res. 2004; 64: 1266-1277. (Pubitemid 38235593)
5. von Levetzow C, Jiang X, Gwye Y, et al. Modeling initiation of Ewing sarcoma in human neural crest cells. PLoS One. 2011; 6: e19305.
6. Hu-Lieskovan S, Zhang J, Wu L, Shimada H, Schofield DE, Triche TJ,. EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Cancer Res. 2005; 65: 4633-4644. (Pubitemid 40740799)
7. Singh SK, Kagalwala MN, Parker-Thornburg J, Adams H, Majumder S,. REST maintains self-renewal and pluripotency of embryonic stem cells. Nature. 2008; 453: 223-227. (Pubitemid 351667975)
8. Gopalakrishnan V,. REST and the RESTless: in stem cells and beyond. Future Neurol. 2009; 4: 317-329.
9. Bruce AW, Donaldson IJ, Wood IC, et al. Genome-wide analysis of repressor element 1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) target genes. Proc Natl Acad Sci U S A. 2004; 101: 10458-10463. (Pubitemid 38924947)
10. Belyaev ND, Wood IC, Bruce AW, Street M, Trinh JB, Buckley NJ,. Distinct RE-1 silencing transcription factor-containing complexes interact with different target genes. J Biol Chem. 2004; 279: 556-561. (Pubitemid 38044858)
11. Gulino A, Arcella A, Giangaspero F,. Pathological and molecular heterogeneity of medulloblastoma. Curr Opin Oncol. 2008; 20: 668-675.
12. Lawinger P, Venugopal R, Guo ZS, et al. The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells. Nat Med. 2000; 6: 826-831. (Pubitemid 30469435)
13. Su X, Gopalakrishnan V, Stearns D, et al. Abnormal expression of REST/NRSF and Myc in neural stem/progenitor cells causes cerebellar tumors by blocking neuronal differentiation. Mol Cell Biol. 2006; 26: 1666-1678.
14. Thiele CJ,. Biology of pediatric peripheral neuroectodermal tumors. Cancer Metastasis Rev. 1991; 10: 311-319.
15. Stewart KS, Zhou Z, Zweidler-McKay P, Kleinerman ES,. Delta-like ligand 4-Notch signaling regulates bone marrow-derived pericyte/vascular smooth muscle cell formation. Blood. 2011; 117: 719-726.
16. Morales-Arias J, Meyers PA, Bolontrade MF, et al. Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration. Cancer. 2007; 110: 1568-1577. (Pubitemid 47463072)
17. Schadler KL, Zweidler-McKay PA, Guan H, Kleinerman ES,. Delta-like ligand 4 plays a critical role in pericyte/vascular smooth muscle cell formation during vasculogenesis and tumor vessel expansion in Ewing's sarcoma. Clin Cancer Res. 2010; 16: 848-856.
18. Riggi N, Cironi L, Suva ML, Stamenkovic I,. Sarcomas: genetics, signalling, and cellular origins. Part 1: the fellowship of TET. J Pathol. 2007; 213: 4-20. (Pubitemid 47354561)
19. Chansky HA, Barahmand-Pour F, Mei Q, et al. Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro. J Orthop Res. 2004; 22: 910-917. (Pubitemid 38756277)
20. Hirschi KK, D'Amore PA,. Pericytes in the microvasculature. Cardiovasc Res. 1996; 32: 687-698. (Pubitemid 26332308)
21. Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G,. PDGFR beta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol. 2005; 7: 870-879. (Pubitemid 41486287)
22. Ackermann M, Morse B, Delventhal V, Carvajal I, Konerding M,. Anti-VEGFR2 and anti-IGF-1R-Adnectins inhibit Ewing's sarcoma A673-xenograft growth and normalize tumor vascular architecture. Angiogenesis. 2012; 15: 685-695.
23. DuBois S, Marina N, Glade-Bender J,. Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data. Cancer. 2010; 116: 749-757.
24. Felgenhauer J, Nieder M, Krailo M, et al. A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: a Children's Oncology Group (COG) Phase II study NCT00061893. Pediatric Blood Cancer. 2013; 60: 409-414.